Background. Tissue from research biopsies provides access to insights into tumor biology. We aimed to determine medical oncologists' (MOs') attitudes toward research biopsies in patients with metastatic breast cancer (MBC). Materials and Methods. A total of 309 breast MOs from National Cancer Institute (NCI)-designated cancer centers were invited to complete a self-administered survey about their attitudes toward approaching patients for research purposeonly biopsies (RPOBs), performed as a standalone procedure, or additional biopsies, performed with a clinically indicated biopsy. The MOs were asked to predict what proportion of their MBC patients would consider undergoing research biopsies. Results. Of the 309 MOs, 221 (72%) responded. Of these 221 MOs, 30 were ineligible, leaving 191 eligible responders. Nearly all the MOs reported they were comfortable approaching patients regarding research biopsies of blood or skin. One
INTRODUCTION
Evaluation of patients' tumors allows insights into the biologic pathways necessary for metastasis and therapeutic resistance. In breast cancer, most molecular data have been generated from primary tumor specimens, and studies of metastatic specimens have been sparse by comparison. However, evidence is accumulating that metastatic tissues can harbor a distinct set of alterations. For example, in the setting of estrogen receptor-positive breast cancer, data from several groups have indicated significant enrichment of estrogen receptor 1 (ESR1) mutations in metastatic specimens relative to primary tumor samples, and this might point to an important resistance mechanism to endocrine therapy [1, 2] . Given the dramatic advances in high-throughput gene sequencing, proteomics, and other technologies, one of the current major limiting factors is the availability of well-annotated metastatic specimens from uniformly treated breast cancer patients.
Research biopsies are performed to collect tissue for scientific studies and have no direct benefit to the patient [3] .
They can either be performed as a stand-alone procedure (research purpose-only biopsy [RPOB] ) or involve additional passes of the biopsy needle at the time of a clinically indicated biopsy (additional biopsy [AB] ). The participation rates in research biopsies are highly variable, between 4% and 97% [4] [5] [6] [7] . Although some of this variability can be explained by differences in study design (i.e., whether it is tied to a therapeutic trial, optional or mandatory biopsies, and the number of biopsy time points), undoubtedly, other factors are at work. For example, in the Translational Breast Cancer Research Consortium study 001, which randomized patients with metastatic triple-negative disease to cetuximab with or without carboplatin, 18 of 102 patients (18%) consented to optional research biopsies on protocol. Significant variation was found in the rate of participation by institution, ranging from 0% (0 of 9) to 56% (5 of 9) of enrolled patients at each of the 12 academic study sites [8] .
Studies have demonstrated that most patients would consider research biopsies [9] [10] [11] , suggesting that nonpatient factors might hinder biopsy accrual. One such nonpatient factor could be provider comfort level in approaching patients for biopsies. Although most research biopsies in recent times have been in the context of clinical trials, limiting research biopsies to those patients enrolled in therapeutic clinical trials for research biopsies greatly diminishes the potential access to such a valuable resource. Our study reports the results of a survey regarding the attitudes of academic medical oncologists (MOs) specializing in breast cancer toward research biopsies outside the context of a clinical trial. We hypothesized that variation would exist in MOs' comfort level in approaching patients with metastatic breast cancer (MBC) for research biopsies. We further hypothesized that MOs underestimate the willingness of patients to undergo research biopsies. In addition, we explored the reasons why MOs might be reluctant to ask patients to participate in such studies. Understanding and addressing MOs' attitudes and concerns could enhance our ability to collect research biopsies and ultimately expand access to tissue for research.
MATERIALS AND METHODS
The present study was conducted in accordance with the Declaration of Helsinki and the Dana-Farber/Harvard Cancer Center institutional review board.
Questionnaire
A study-specific questionnaire was developed to assess MO comfort levels in approaching patients and to gauge their estimates of patient willingness to undergo research biopsies. It was first piloted in a small group of MOs at the DanaFarber Cancer Institute (DFCI). Subsequently, key informant interviews were conducted with MOs outside the DFCI to further assess the face validity and clarity of content.The final questionnaire, which had not been previously validated, was a 28-item survey of clinical scenarios determining MOs' attitudes toward research biopsies and physician demographics. In the questionnaire, we did not specify whether the requests for research biopsies were in the context of therapeutic clinical trials or purely for tumor banking, because we sought to assess the attitudes of MOs regarding research biopsies disassociated from therapeutic trial requirements. MOs were asked who they thought would be the best person to approach patients for research biopsies. MOs indicated how comfortable they were in approaching patients with MBC to participate in RPOBs and ABs on a 4-point Likert scale (very comfortable, somewhat comfortable, somewhat uncomfortable, very uncomfortable). For the purposes of the present analysis, we classified "very comfortable" and "somewhat comfortable" as "comfortable" and the rest as "uncomfortable." The MOs' comfort levels in approaching patients for research venipunctures and biopsies of skin, breast, and liver were also assessed. In addition, they were asked to estimate what proportion of their typical patients with MBC would consent to RPOBs and ABs. Finally, the barriers that might hinder them from approaching patients for research biopsies were assessed.
Participants
Initially, both academic and community-based MOs were identified. Academic MOs with a listed specialty area of breast cancer were identified from the websites of each of the National Cancer Institute (NCI)-designated cancer centers. For community MOs, we began with a random entry within the American Society of Clinical Oncology alphabetical directory listing and selected every eighth member who listed their specialty as medical oncology. MOs who did not see breast cancer patients or who saw patients ,4 hours each week were excluded. Because of concern about the response rate, the survey was performed in two stages. The study met the protocol prespecified rule to continue enrollment to stage 2. However, the response rate for academic MOs (60%) was higher than that for community MOs (20%). Thus, in stage two, we chose to proceed with academic MOs only. The surveys were completed in the period of May 2012 to March 2013. MOs received a prenotification letter explaining the study and $5. An electronic mail (e-mail) letter containing the link to participate in the online survey was sent 1 week later. Reminder e-mail letters were sent to nonresponders at 2 and 3 weeks. For nonresponders at 4 weeks, the MO's office was telephoned to determine the accuracy of their contact information, eligibility criteria, and whether an alternate method of receiving the survey was preferred. If the MO had a preferred method of receiving the survey (excluding online), the survey was mailed or sent by facsimile. A $100 gift certificate was given on completion of the survey.
Statistical Analysis
The primary endpoint was the MO comfort level in approaching patients with MBC to participate in RPOBs and ABs, analyzed as a dichotomous variable. Greater participation in clinical trials, measured by the number of patients the MO had enrolled per month into clinical trials was the independent variable of interest. Experience, measured by years in practice, and having a recent patient undergoing a research biopsy were also thought to be related to an MO's comfort level.To evaluate the relationship of participation in clinical trials and comfort level, univariate and multivariable analyses were performed. Multivariable adjustments included years in practice, gender, and having a recent patient undergo a biopsy. Age was excluded, because it correlated highly with the number of years in practice. Unadjusted and adjusted relative risks (RRs) and 95% confidence intervals (CIs) were determined using Poisson regression [12] . All other CIs for binomial proportions were determined using exact methods. The tests were 2-sided at the .05 significance level [13, 14] .
RESULTS
Of the 309 MOs invited to participate, we received responses from 221 (72%). Of these, 30 MOs were deemed ineligible (supplemental online Fig. 1 ). A total of 191 (101 women, 85 men, 5 gender unknown) eligible MOs completed the survey. Their median age was 50 years (range, 33-80). The median duration of oncology experience was 15 years (range, 1-45; Table 1 ). Most oncologists thought that the patient's primary oncologist would be the optimal person to approach a patient for participation in a clinical trial or research biopsy (supplemental online Fig. 2 ).
Research Biopsies of Different Organs
Nearly all (98%) MOs were comfortable approaching patients for venipuncture, either as a standalone research procedure or at the time of a clinically indicated venipuncture ( Table 2 ). More than 90% of MOs were comfortable asking patients to provide RPOBs or ABs of the skin. Fewer MOs were comfortable approaching patients for breast or liver biopsies: 78% and 93% for RPOBs and ABs of the breast and 50% and 70% for RPOBs and ABs of the liver, respectively.
Factors Associated With RPOBs and ABs
MOs whose patients had recently undergone research biopsies were more likely to express comfort in approaching patients with MBC for a RPOB of the breast (RR, 1.4; 95% CI, 1.1-1.8; p , .01) or liver (RR, 2.3; 95% CI, 1.5-3.6; p , .01). In addition, MOs who had been in practice for fewer than 15 years were more likely to be comfortable approaching patients for an RPOB of the breast (RR, 1.2; 95% CI, 1.0-1.3; p 5 .04; Table 3 ). Being in practice for ,15 years (RR, 1.3; 95% CI, 1.1-1.5; p 5 .01) and having patients who had recently undergone research biopsies (RR, 1.4; 95% CI, 1.1-1.7; p 5 .01) were also factors associated with increased comfort in discussing an AB of the liver.
MOs' Estimation of Patient Willingness to Undergo Tissue Collection
Most MOs reported being very or somewhat confident about their predictions of patient willingness to undergo blood and tissue collection. When asked as a general (i.e., non-sitespecific) question, 16% and 87% of MOs responded that their typical MBC patient would definitely or probably participate in RPOBs and ABs, respectively. No MOs predicted that their typical patient would definitely or probably decline an AB. However, when asked in a site-specific manner, MOs predicted that 90%, 60%, 33%, and 20% of their patients would definitely or probably consider RPOBs of the blood, skin, breast, or liver, respectively. MOs predicted that 90%, 75%, 70%, and 50% of their patients would definitely or probably consider ABs of the blood, skin, breast, or liver, respectively ( Fig. 1; Table 4 ).
As shown in Figure 1 , substantial variation was found between MOs in their estimated distributions of patient attitudes. For example, MOs' estimates of patient willingness for RPOB of the breast ranged from 0% to 100% and for RPOB of the liver ranged from 0% to 90%. The interquartile range (quartile 1 to quartile 3) remained similarly wide; 20%-60% for RPOBs of the breast and 30%-75% for ABs of the liver.
Association Between MOs Estimates of Patient Attitudes and MO Comfort Level
After noting the variation in MO estimates of patient willingness toward research biopsies, we assessed whether MO estimates were associated with their comfort level in approaching patients for research biopsies. MOs who perceived higher patient willingness to undergo research biopsies were more likely to be comfortable approaching patients for such procedures (Table 5 ). For example, among MOs who estimated that fewer than 25% of their patients would consent to an RPOB of the breast, 29 of 71 (41%) indicated discomfort with approaching a patient for this procedure compared with only Oncologists' Attitudes Toward Biopsies 6 of 61 MOs (10%), who estimated that 26%-50% of their patients would agree.
Reasons for MOs' Reluctance Toward Research Biopsies
The 3 most common reasons cited by MOs reluctant to refer patients for participation in RPOBs included the risk of a biopsy (n 5 137, 72%), the pain or discomfort of a biopsy (n 5 134, 70%), and inconvenience to patients (i.e., time involved, travel; n 5 58, 30%).These reasons were similar for AB: risk of a biopsy (n 5 128, 67%), pain/discomfort of a biopsy (n 5 125, 65%), and logistical barriers (i.e., scheduling; n 5 42, 22%).
Concerns about whether such studies are ethical or useful, about the lack of direct benefit to patients, patient anxiety, and time factors were not prevalent. Only 1% of MOs cited ethical concerns regarding approaching patients for research biopsies (Table 6 ).
DISCUSSION
We surveyed academic MOs caring for breast cancer patients at NCI-designated cancer centers about their comfort levels in approaching their patients with MBC for research biopsies, perceptions of patient willingness to undergo research biopsies, and perceived barriers to research biopsies outside the context of a clinical trial.To our knowledge, this is the first study to systematically survey academic MOs specializing in breast cancer on this key issue. We found that although most MOs reported being comfortable approaching patients for venipuncture or skin biopsies, more than one fifth were uncomfortable approaching patients for RPOB of the breast and one half were uncomfortable approaching patients for RPOB of the liver. In general, MOs reported greater comfort approaching patients for additional biopsies at the time of a planned clinical procedure; however, 30% of MOs reported discomfort in approaching patients for ABs of the liver. The major barriers that MOs expressed regarding biopsies were concerns about the risks of a biopsy, biopsy-related pain, and logistical arrangements. MOs reported that ethical issues, lack of direct patient benefit, and concerns regarding scientific yield were less important barriers. Biopsy site, numbers of years in practice, and previous experience with research biopsies were important factors influencing MOs' comfort with approaching patients for research biopsies.
Because the vast majority of MOs were comfortable approaching patients for venipuncture and skin biopsies, it appears that MOs are comfortable approaching patients for low-risk research procedures, even without direct patient benefit. MOs most commonly cited the risks of, and pain from, the biopsy procedure as barriers to pursuing research biopsies. This finding is concordant with data from patient surveys [15, 16] . It is noteworthy, however, that most studies have suggested research biopsies are safe, with a 0.8%-1.4% major complication rate [4] [5] [6] 17] . For example, of 61 patients who underwent a liver biopsy in a prospective tissue collection study at DFCI, only 1 grade 2 or higher adverse event (grade 2 pain) was noted [7] . However, we did not include questions in our survey regarding the perceived risks of breast or liver biopsies that would have helped us to determine whether MOs' discomfort could be explained by inaccurate risk perceptions. Previous research has suggested that patients might be more willing to accept risks from a research procedure than clinicians would deem acceptable [10] . Fewer years in practice might represent a younger generation of MOs who have trained in an environment in which research biopsies are increasingly included in clinical trials. Because this was a cross-sectional study, we were unable to determine whether having patients who had undergone research biopsies in the previous 3 months resulted from MOs' comfort levels or vice versa.
We previously conducted a study surveying 160 MBC patients in the northeast United States about their attitudes toward research biopsies. In that study, 50% and 70% of patients would consider undergoing RPOBs and ABs, respectively [15] . However, in the present study, 16% and 85% of the MOs estimated that their typical patient would definitely or probably consent to an RPOB and AB, respectively. MOs estimated that 90%, 60%, 33%, and 20% of their patients would consider RPOBs of the blood, skin, breast, and liver, respectively. This is qualitatively similar to the patient responses in the patient questionnaire, in which 90%, 60%, 44%, and 21% of the patients would consider participating in RPOBs of the blood, skin, breast and liver, respectively. It is in contrast to our initial hypothesis that MOs might systematically underestimate patient willingness to undergo research procedures [15] . However, underlying these averages were dramatic variations in individual MOs' estimates of patient willingness toward research biopsies, with some MOs' predicting that only a few of their patients would be willing to undergo research biopsies of various sites Table 4 . Medical oncologists' estimation of the proportion of metastatic breast cancer patients who would consent to research purpose-only biopsies and additional biopsies Table 5 . Relationship between medical oncologists' estimation of patient willingness to undergo research biopsies and medical oncologists' comfort level in approaching patients for research biopsy
Estimated proportion of patients who would consent to research biopsy (n 5 191) 0%-25% 26%-50% 51%-75% 76%-100% Unknown
Research purpose-only biopsies of the breast  Comfortable  42  55  29  19  4  Not comfortable  29  6  1  0  3  Unknown  0  0  0  0  3  Research purpose-only biopsies of the liver  Comfortable  44  30  10  5  7  Not comfortable  74  11  0  0  6  Unknown  0  1  0  0  3  Additional biopsies of the breast  Comfortable  13  44  42  76  2  Not comfortable  4  3  1  3  0  Unknown  0  0  0  0  3  Additional biopsies of the liver  Comfortable  13  48  28  41  4  Not comfortable  25  16  8  3  2  Unknown  0  0  0  0  3 www.TheOncologist.com
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and others predicting that most patients would be willing. For example, for RPOBs of the liver, MOs' estimates of patient willingness ranged from 0% to 90%.The MOs cited risks, pain, and logistical factors as the primary barriers to research biopsies. In actuality, predicted patient willingness to undergo biopsies was strongly associated with MO comfort level in approaching patients, although this was not an issue that MOs perceived as a major barrier. This is consistent with evidence in the published social psychology data that the expected response to requests can influence the decision to make requests in the first place [18, 19] . It is also possible that MOs perceive that approaching patients who are unlikely to agree to a biopsy is more time-consuming, although a lack of time was only infrequently cited as a major barrier overall.
Because of the design of the study, we were unable to determine whether MOs' predictions of their own patients' attitudes accurately reflected true differences in patient attitudes across practices versus inaccurate MO perceptions. However, this takes on new relevance if these inaccurate perceptions inhibit MOs from approaching patients about such studies.
Our study had a number of limitations. The survey was not validated, because we were unaware of any validated measures to address the research questions we posed. In addition, just as with any survey, it would be reasonable to assume that nonresponse bias might have been present. We did not collect detailed information on nonresponders that would have allowed us to determine whether any key characteristics were present that would differentiate responders from nonresponders that might have affected study results.The present report was limited to MOs practicing at NCI comprehensive cancer centers and might not reflect the opinions of community-based MOs. Recruitment of communitybased MOs was initially attempted; however, because of the low response rate (20%), which would have precluded any meaningful conclusions, the study was adjusted to focus on the views of academic MOs. Because most patients are treated in the community, determining community medical oncologists' comfort level and the barriers they might face in approaching patients to participate in research biopsies is an important issue. Future research, including conducting key informant interviews of community medical oncologists, might be 
CONCLUSION
We have demonstrated striking variations in the comfort level of MOs in approaching patients for research biopsies in the setting of MBC and widely divergent predictions of the willingness of their patients to undergo biopsies. To the extent that MOs serve as "gatekeepers" with respect to tissue collection, we believe our findings are relevant to inform current and future practice. Physicians who are uncomfortable approaching patients about undergoing research biopsies might convey their discomfort both intentionally and unintentionally and might thereby significantly influence their patients' likelihood to consent to tissue collection efforts. MOs who perceived a higher patient willingness to undergo research biopsies were more likely to be comfortable approaching patients for biopsies, suggesting that a strong element of physician-patient communication and physician-patient education exists that might be modifiable to increase participation in research biopsies. Multiple interventions could be implemented on many levels to increase patient participation in research biopsies. We believe that providing oncologists with education about the risks of biopsies in real-world experience might increase the comfort level of the oncologist. From a practical perspective, improving working relationships and feedback mechanisms between MOs and the providers who perform biopsies (i.e., surgeons, interventional radiologists), with attention to mitigating risks, optimizing pain control, and flexibility in scheduling (to reduce patient inconvenience) could also be helpful. Increasing the number of clinical trials with the option for a research biopsy might also increase familiarity and improve the comfort levels of medical oncologists to approach patients for research biopsies. Finally, greater awareness among both providers and patients regarding the rich resource that tissue provides to deepening our understanding of tumor biology might increase the enthusiasm of providers to approach patients and for patients to even proactively discuss biopsies with providers. Increasingly, a research imperative exists to collect tissue from patients with MBC, either at recurrence or on progression, particularly as we seek to develop and understand targeted therapies. If, as a medical and scientific community, we are convinced that tissue-based research is critical and if the risk is deemed sufficiently low enough to be acceptable, MOs' attitudes could be a potential target for education and change. More research is needed to understand interventions that might influence MOs' comfort levels in asking patients to participate in such studies. Based on our data, we propose enhanced educational efforts aimed at both patients and physicians and improvements in infrastructure to reduce the logistical barriers. In addition, we propose mechanisms to track and report complication rates and guidance to address the pain and discomfort associated with such procedures. Finally, we believe improved communication among MOs, radiologists, pathologists, and surgical colleagues should be aggressively pursued to improve understanding of the importance of research biopsies for scientific advancement and to facilitate the collection of tissue samples for research. System level approaches to allow patients to signal their interest in a research biopsy and to facilitate consent discussions could also be considered.
